LCLarisa H. Cavallari

Larisa H. Cavallari

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Larisa H. Cavallari has a total of 871 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Characterizing Resources and Workforce Needs for Pharmacogenomics Programs Worldwide: Pharmacogenomics Global Research Network Implementation Working Group Landscape Survey

    by Amanda L. Elchynski, James M. Stevenson, Ronald Campbell, Benjamin Q. Duong, Nihal El Rouby, Christina L. Aquilante, Hana Al Alshaykh, Salma A. Bargal, Rebecca Brand, Larisa H. Cavallari, et al.

  • Real‐World Comparative Effectiveness and Safety of Prasugrel Versus Ticagrelor After Acute Coronary Syndrome and Percutaneous Coronary Intervention

    by Munaza Riaz, Dominick J. Angiolillo, Craig R. Lee, Larisa H. Cavallari

    Study Objective: To compare the real‐world effectiveness and safety of prasugrel versus ticagrelor among patients with acute coronary syndrome (ACS) who underwent percutaneous coronary intervention (PCI) in the United States. Design: Retrospective new‐user cohort study. Data Source: MarketScan Research Databases, 2017–2023. Patients: Patients aged 18 years or older with ACS and PCI initiated on either prasugrel or ticagrelor were identified using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD‐10‐CM) diagnosis codes and prescription records. The prescription fill date was assigned as the index date. Patients were required to have continuous enrollment in their health care plan for 1 year prior to and including the index date. Measurements and Main Results: Stabilized inverse probability treatment weighting was applied to balance baseline characteristics between treatment groups. Cox proportional hazards models with adherence adjustment were used to estimate 1 year risk of major adverse cardiovascular events (MACE, composite of myocardial infarction [MI], ischemic stroke, or stent thrombosis), bleeding events, and individual MACE components. The study included 6662 prasugrel‐treated and 25,452 ticagrelor‐treated patients. Prasugrel was associated with a lower risk of MACE (3.83 vs. 5.61 events per 100 person‐years; adjusted hazard ratio [aHR] 0.72, 95% confidence interval [CI] 0.65–0.92) and MI (3.43 vs. 4.73 events per 100 person‐years; aHR 0.80, 95% CI 0.66–0.97) compared with ticagrelor, respectively. Bleeding risk did not differ between prasugrel versus ticagrelor (2.85 vs. 3.89 events per 100 person‐years, respectively; aHR 0.92, 95% CI 0.74–1.13). Sensitivity analyses restricted to patients with high medication adherence and without contraindications to prasugrel showed similar results. Conclusion: Among commercially insured US patients with ACS undergoing PCI, prasugrel was associated with a lower risk of ischemic cardiovascular events compared with ticagrelor, without an increase in bleeding risk, including in patients with high medication adherence. These findings provide contemporary real‐world evidence supporting the preferential use of prasugrel over ticagrelor following ACS and PCI in appropriately selected patients.

  • Open Access

    Defining Core Functions and Forms for the Implementation of Pharmacogenomics Testing in Primary Care

    by Sanjana Ramesh, Larisa H. Cavallari, Victoria Wittner, Josiah Allen, Mari Angelica S. Cayabyab, Emily J. Cicali, Nihal El Rouby, Shayna R. Killam, Nita Limdi, Mohamed Nagy, et al.

    Pharmacogenomics (PGx), utilizing a patient's DNA to individualize medication prescribing, minimizes adverse events and improves patient outcomes. However, the integration of PGx into primary care remains sparse. PGx testing encompasses multiple components and can be considered a complex health intervention. We conducted an in‐person workshop with early adopters from the Pharmacogenomics Global Research Network Implementation Working Group, followed by qualitative interviews with key opinion leaders, to identify the core functions and forms necessary for implementing PGx testing in primary care. Workshop participants agreed on six core functions necessary to implement PGx‐guided medication prescribing in primary care settings: patient identification, test ordering, laboratory testing, returning results, providing medication recommendations, and modifying pharmacotherapy. An additional function, leadership engagement, was proposed by key opinion leaders. There was considerable variation in the forms, depending on local context and available resources. In this position paper, we discuss why it is critical to separately define the core functions required to implement PGx testing in primary care settings and the customizable forms used for local execution. Defining core functions provides an actionable first step to guide scalable and context‐sensitive integration of PGx testing into routine primary care practice, balancing the need for both fidelity and adaptation in real‐world implementation.

  • Open Access

    A Pilot Randomized Study of NAT2 and YEATS4 Pharmacogenetic Return of Results in Adults with Hypertension and African Ancestry: The GUARDD ‐ US PGx Study

    by Philip E. Empey, Nita A. Limdi, Dinushika Mohottige, Kady‐Ann Steen‐Burrell, Hrishikesh Chakraborty, Khoa A. Nguyen, Alexander S. Parker, Emily J. Cicali, Girish N. Nadkarni, Michelle A. Ramos, et al.

    Almost half of individuals with hypertension fail to achieve recommended blood pressure (BP) goals. Pharmacogenetic gene‐drug interactions may alter the efficacy of antihypertensive agents. We conducted a multicenter randomized controlled sub‐study of participants ( N = 1874) with hypertension and self‐reported African ancestry to determine whether pharmacogenetic return of results (RoR) would improve systolic blood pressure (SBP) at 3 months. Participants were randomized to immediate pharmacogenetic RoR (intervention) or delayed RoR at trial completion (control). Clinical decision support conveyed recommendations for YEATS4 ‐guided thiazide diuretic selection and NAT2 ‐guided hydralazine dosing. Prespecified subgroup analyses included those with uncontrolled BP (baseline SBP ≥140 or DBP ≥90 mm Hg) and actionable genotypes. Immediate RoR did not improve SBP at 3 months in a broad population of hypertensive adults with controlled and uncontrolled SBP (covariate‐adjusted change in SBP between groups: −0.3 ± 0.74 mm Hg, 95% CI: −1.8, 1.2). In participants with an actionable YEATS4 genotype ( N = 867) predicting reduced thiazide efficacy, immediate RoR led to greater SBP reduction at 3 months (−2.46 mm Hg, 95% CI: −4.57 to −0.36). In participants with uncontrolled hypertension at baseline ( N = 659), immediate RoR led to a greater reduction in SBP (−2.9 ± 0.74 mm Hg, 95% CI: −5.6, −0.3). Although no SBP reduction was observed in the whole cohort, participants with an actionable YEATS4 genotype or uncontrolled BP who received immediate RoR had a significantly greater SBP improvement than those with delayed RoR. Future studies of antihypertensive pharmacogenetics should recruit individuals with uncontrolled BP and actionable genotypes.

  • Open Access

    CYP2D6 ‐Guided Opioid Therapy for Chronic Pain: A Multi‐Center Pragmatic Randomized Controlled Trial

    by Todd C. Skaar, Rachel A. Myers, Roger B. Fillingim, John T. Callaghan, Kerri L. Cavanaugh, Hrishikesh Chakraborty, Jordan F. Baye, Emily J. Cicali, Michael T. Eadon, Erica N. Elwood, et al.

    The analgesic effectiveness of several opioids depends on CYP2D6‐mediated metabolism to more active opioid receptor agonists. CYP2D6 activity is impacted by genetic variability and medications that inhibit CYP2D6. We conducted a pragmatic, multi‐center, randomized, controlled trial to determine whether CYP2D6‐guided opioid prescribing improves chronic pain. Participants were adults recruited from primary care or pain specialty clinics with at least 3 months of chronic pain treated or considered for treatment with tramadol, hydrocodone, or codeine. Participants were randomized to the usual care or CYP2D6‐guided arm, in which CYP2D6 pharmacogenetic testing was performed. Healthcare professionals were recommended to avoid tramadol, hydrocodone, or codeine in patients with CYP2D6 intermediate or poor or ultra‐rapid (for safety) metabolizer phenotypes based on either genotype or drug interactions. The primary outcome was the change in composite pain intensity scores from baseline to 3 months. Of 1048 enrolled participants, 282 had an actionable CYP2D6 phenotype. In this group, CYP2D6‐guided recommendations did not improve the change in composite pain intensity scores from baseline to 3 months compared with usual care (mean [SD] −0.8 [2.4] vs. −0.7 [2.3]) or improve drug‐gene concordance (26.8% vs. 27.1%) in the CYP2D6‐guided versus usual care arm, respectively. In an exploratory analysis, participants whose therapy changed to align with their CYP2D6 phenotype had significantly improved pain scores. In conclusion, incorporating CYP2D6‐guided recommendations for opioid therapy into routine practice did not change prescribing sufficiently to assess its impact on chronic pain control, suggesting that EHR‐integrated CYP2D6 guidance is insufficient to change opioid prescribing for chronic pain.

  • Open Access

    Tramadol Co‐Administration with Oxycodone or Hydrocodone Increases Opioid Burden without Improving Postoperative Pain Control

    by Noor A. Nahid, Ahmed I. Soliman, Jordan F. Baye, Natasha J. Petry, Chancellor F. Gray, Rachel A. Myers, Erica N. Elwood, Elizabeth C. Harris, Hrishikesh Chakraborty, Simona Volpi, et al.

    Tramadol is frequently co‐prescribed with oxycodone or hydrocodone after surgery under the assumption that its dual mechanism of action provides an opioid‐sparing benefit. However, evidence supporting this practice is limited and inconsistent. We conducted a secondary analysis of the multicenter IGNITE ADOPT‐PGx pragmatic trial of patients undergoing elective surgery who were prescribed oxycodone alone ( n = 317) versus tramadol + oxycodone ( n = 96), or hydrocodone alone ( n = 563) versus tramadol + hydrocodone ( n = 42). Co‐primary outcomes of this study were cumulative morphine milligram equivalents (MME) consumed during the 10 days following surgery and composite pain scores at day 10 defined as the sum of current pain and average and worst pain in the past 7 days (score ranges from 3 to 15). Inverse probability of treatment weighting (IPTW) was used to adjust for demographic characteristics, comorbidities, and concomitant analgesics. Sensitivity analyses restricted to CYP2D6 normal metabolizers and sites prescribing both monotherapy and combination therapy and subgroup analysis including total knee arthroplasty patients were conducted. Compared to oxycodone alone, the combination of oxycodone and tramadol was associated with higher MME (adjusted mean 205.2 vs 122.5; P < 0.0001) and lower mobility, without meaningful differences in pain scores (adjusted mean 9.6 vs 9.4; P = 0.41 ). Similar findings were observed for hydrocodone‐only vs hydrocodone + tramadol groups. Results were consistent in sensitivity and subgroup analyses. Co‐administration of tramadol with oxycodone or hydrocodone was associated with substantially higher total MME and reduced mobility without any demonstrable improvement in pain control.

  • Open Access

    CYP2C19 Genotyping to Guide Clopidogrel Prescribing for Neurovascular Indications: A Survey of Institutional Approaches

    by Rachael M. Stone, Glenda Hoffecker, April Schultz, Brittney H. Davis, Salma A. Bargal, Amber L. Beitelshees, Nihal El Rouby, Madeline Norris, Kevin J. Rodriguez, Nita Limdi, et al.

    Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is commonly used for secondary prevention following acute ischemic stroke (AIS) and neurointerventional procedures. However, the efficacy of clopidogrel is reduced in carriers of CYP2C19 no‐function alleles. While CYP2C19 ‐guided DAPT is well‐established for some cardiovascular indications, its use in neurovascular settings has remained limited until recently. This study characterized current implementation strategies for CYP2C19 ‐guided DAPT for neurovascular indications across institutions in the Pharmacogenomics Global Research Network Implementation Working Group. A REDCap survey was distributed to 54 institutions targeting those currently utilizing or planning to implement CYP2C19 testing to guide clopidogrel use for neurovascular indications. The survey collected data on implementation status, workflows, testing logistics, clinical decision support (CDS), and guideline concordance. Fifteen institutions met inclusion criteria; 80% were in the United States and 87% were academic centers. CYP2C19 testing was used for neurovascular indications at 12 sites, most commonly for AIS, intracranial aneurysm repair, and intracranial stenting. Implementation was often built on infrastructure previously established for cardiovascular indications. Most sites used multigene panels, offered testing in both inpatient and outpatient settings, and returned results within 7 days. Eighty percent of sites provided CDS to support application of results. All sites recommended an alternative P2Y12 inhibitor (e.g., ticagrelor) for poor metabolizers, and most did for intermediate metabolizers. CYP2C19 ‐guided antiplatelet therapy for neurovascular indications is expanding, with many implementations leveraging preexisting infrastructure from cardiovascular settings. Broader adoption and outcome‐focused research are needed to optimize the clinical utility of genotype‐guided DAPT in neurovascular care.


  • Open Access

    Machine Learning With Genetic and Clinical Data to Predict Ischemic Outcomes After PCI

    by Caroline W. Grant, Brenden S. Ingraham, Ryan J. Lennon, Anvi Raina, Shulan Tian, Gurukripa Kowlgi, Larisa H. Cavallari, Craig R. Lee, Amber Beitelshees, Dominick J. Angiolillo, et al.

    Ischemic events after contemporary percutaneous coronary intervention (PCI) are uncommon but carry high morbidity/mortality. Identifying patients at highest risk is critical to guide dual antiplatelet therapy (DAPT) intensity while minimizing bleeding. Current machine learning (ML) model‐developed risk scores do not incorporate pharmacogenetic data. To develop and externally validate ML models that integrate clinical, demographic, and CYP2C19 genetic information to predict 1‐year ischemic outcomes post‐PCI to refine clinical decision making. We analyzed 8317 patients from TAILOR‐PCI trial ( n = 4572) and the Precision PCI registry ( n = 3745). The outcome was a composite of cardiovascular death, myocardial infarction, stroke, and stent thrombosis at 1 year. Boruta feature selection identified 11 predictors. Multiple ML algorithms were trained in TAILOR‐PCI and validated in Precision PCI using cross‐validation and synthetic minority oversampling (SMOTE). Model performance was assessed by area under the receiver operating characteristic curve (AUC), sensitivity, and specificity. The best external performance was achieved with a support vector machine (SVM, polynomial kernel) (AUC 0.667; sensitivity 0.871; specificity 0.282), while XGBoost provided a more balanced profile (AUC 0.619; sensitivity 0.442; specificity 0.688). Variable importance for the SVM polynomial model demonstrated that all 11 included Boruta feature selected predictors had relatively high importance (> 75). ML models trained on large clinical trial and real‐world registry datasets can help identify the small subset of patients at high ischemic risk after PCI. This distinction is of relevance because ischemic events are rare, and most patients may safely de‐escalate DAPT to reduce bleeding risk while maintaining ischemic protection through a multimodal approach to risk stratification. Trial Registration: TAILOR‐PCI URL: https://clinicaltrials.gov/ct2/show/NCT01742117

  • Open Access

    2025 Acute Coronary Syndrome Guideline: Missing the Boat on CYP2C19 Genotyping

    by Larisa H. Cavallari, Craig R. Lee, Amber L. Beitelshees, Jasmine A. Luzum, George A. Stouffer, Jurriën M. Ten Berg, Wout W. A. van Den Broek, Naveen L. Pereira, Dirk Sibbing, Dominick J. Angiolillo

    The 2025 American College of Cardiology/American Heart Association/American College of Emergency Physicians/National Association of Emergency Medical Services Physicians/Society for Cardiovascular Angiography & Interventions acute coronary syndrome guideline focuses on strategies to reduce bleeding risk with antiplatelet therapy yet lacks any recommendation related to CYP2C19 genotyping. The impact of CYP2C19 loss‐of‐function alleles on the effectiveness of clopidogrel is well documented, and although prasugrel and ticagrelor more effectively reduce the risk for atherothrombotic events compared with clopidogrel in patients with a CYP2C19 loss‐of‐function allele, clopidogrel reduces bleeding risk without an increase in atherothrombotic events compared with prasugrel or ticagrelor in those without a loss‐of‐function allele. Accordingly, an American Heart Association Scientific Statement supports CYP2C19 genetic testing before oral P2Y 12 inhibitors are prescribed. This commentary summarizes the evidence in support of CYP2C19 ‐guided P2Y 12 inhibitor selection in the context of other 2025 acute coronary syndrome guideline recommendations and urges future guidelines to incorporate recommendations for CYP2C19 genotyping, especially for those at high bleeding risk.


  • Open Access

    Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention

    by Danwei Shao, Jean G. Malavé, Joseph S. Rossi, Francesco Franchi, Ellen C. Keeley, Dominick J. Angiolillo, George A. Stouffer, Larisa H. Cavallari, Craig R. Lee

    CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/rapid/ultrarapid metabolizers: NM/RM/UMs). However, the impact of CYP2C19 or CYP3A4 inhibitor use on clopidogrel clinical effectiveness remains unclear. Rates of major atherothrombotic events (MAE) over 12 months after percutaneous coronary intervention (PCI) were evaluated in 3,242 patients across three sites who underwent CYP2C19 genotype testing and received P2Y 12 inhibitor therapy. Overall, 6.8% of patients were co‐prescribed a moderate or strong inhibitor of either CYP2C19 or CYP3A4, as defined by the U.S. Food and Drug Administration. In CYP2C19 genotype‐predicted NM/RM/UMs treated with clopidogrel ( n = 1,624), the MAE rates were numerically higher, but not significantly different in patients receiving either a CYP2C19 or a CYP3A4 inhibitor vs. no inhibitor (18.4 vs. 12.8 events/100 patient‐years, adjusted hazard ratio (HR) 1.51, 95% confidence interval (CI), 0.85–2.68, P = 0.155). When evaluating CYP2C19 inhibitor and CYP3A4 inhibitor use separately, MAE rates were higher in clopidogrel‐treated NM/RM/UMs receiving a CYP2C19 inhibitor compared to no inhibitor (adjusted HR 2.22, 95% CI 1.01–4.91, P = 0.048), but no significant difference was observed in those receiving a CYP3A4 inhibitor compared to no inhibitor (adjusted HR 1.26, 95% CI 0.57–2.75, P = 0.569). These results suggest that concomitant use of a CYP2C19 inhibitor, but not a CYP3A4 inhibitor, may contribute to phenoconversion and decreased clopidogrel clinical effectiveness after PCI in CYP2C19 genotype‐predicted NM/RM/UMs.